CELNOVA PHARMA ANNOUNCES AVAILABILITY OF APOKINON® IN ARGENTINA
Celnova Pharma announced today that APOKINON® (apomorphine self-injection pen) to treat loss of control of body movements (on-off periods) in people with advanced Parkinson’s disease (PD) is available in every pharmacy in Argentina.
APOKINON® is commercialized in Argentina under a new exclusive distribution agreement signed between Celnova Pharma y Laboratoire Aguettant from France.
APOKINON® is the only available therapeutic option to treat motor fluctuations (‘on-off’ phenomena) in patients with Parkinson’s disease which are not sufficiently controlled by oral anti-Parkinson medication.
About Celnova Pharma
Celnova Pharma is a pharmaceutical company focused in complex therapeutic classes such as oncology, central nervous system and critical care. Celnova has established operations in Argentina and Chile, and is in process of opening its Peru and Colombia subsidiaries.
Celnova’s business model combines proprietary branded generics with in-licensing of established drugs from multinational companies and patent-protected unique drugs.
Celnova´s long term goal is to grow in Latin America through a mix of organic growth and selected acquisitions and partnerships. For more information, please visit www.celnova.com
Celnova Pharma is a registered trademark of Celnova Argentina S.A.